- Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
- Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
- Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
- Xencor to Present at Upcoming Investor Conferences
- Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer
- Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
- Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
More ▼
Key statistics
On Friday, Xencor Inc (XNCR:NMQ) closed at 49.27, -15.55% below its 52-week high of 58.35, set on Feb 24, 2021.
52-week range
Markit short selling activity
Open | 46.98 |
---|---|
High | 51.55 |
Low | 46.64 |
Bid | 40.98 |
Offer | 0.00 |
Previous close | 46.76 |
Average volume | 220.94k |
---|---|
Shares outstanding | 57.95m |
Free float | 56.29m |
P/E (TTM) | -- |
Market cap | 2.85bn USD |
EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of Feb 26 2021 21:00 GMT.
More ▼